Jakavi® is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
Rapid Review
| Commenced | Completed | Outcome |
| 15/04/2015 | 28/05/2015 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 13/04/2016 | 16/08/2016 | Reimbursement Not Recommended |